Product
Indication
In vitro Confirmationof Lead Candidate
Efficacy Study inAnimal Model
Candidate Confirmation
Pre-clinical
Clinical
Bispecific antibody
BAB-05
Hematological malignancies
Pre-clinical---IND expected in 2026-Q2
BAB-09
Prostate Cancer
Pre-clinical---IND expected in 2026-Q4
BAB-0120
NSCLC
Pre-clinical
AF-29
Rare disease/Acute gouty arthritis
Pre-clinical--- IND expected in 2026-Q1
BIC-020
Colorectal Cancer
Pre-clinical---IND expected in 2026-Q3
BIC-021
HSNCC/solid tumor
Candidate Confirmation
ICM-022
Castration -resistant prostate cancer
Pre-clinical
lCM-053
Solid/Hematological cancer
Candidate Confirmation
Bispecific antibody conjugates
BTA-010
NSCLC
Pre-clinical---IND expected in 2026-Q3
BTA-032
Prostate Cancer
Candidate Confirmation
BTA-0120
AML
Efficacy Study inAnimal Model
Recombinant proteins
Monoclonal antibodies
Epitope-directed mAbs
MAB105
Immune modulator/Sepsis/RA
Pre-clinical